Verrica Pharmaceuticals Strives for Nasdaq Compliance

The latest announcement is out from Verrica Pharmaceuticals ( (VRCA) ).

Verrica Pharmaceuticals Inc. finds itself temporarily non-compliant with Nasdaq’s independent director requirement following the immediate resignation of board member Craig Ballaron. The company has appointed Diem Nguyen to the Audit Committee, signaling steps toward rectifying the issue. Nasdaq has granted a cure period for compliance, which extends until the company’s next annual stockholders meeting or October 2, 2025, whichever comes first. If the meeting occurs before March 31, 2025, the company must comply by that date. Verrica Pharmaceuticals is confident it will meet the requirements within the provided timeframe.

See more data about VRCA stock on TipRanks’ Stock Analysis page.